# CV Sciences, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/CV Sciences, Inc.).

## Overview

CV Sciences, Inc. is a U.S.-based consumer products and development company focused on hemp-derived CBD products and related herbal supplements, with an additional drug development program centered on CBD-based therapeutics. The company sells branded consumer products and also appears to participate in contract manufacturing activity, while continuing to evaluate acquisitions to broaden its platform. Its operations are shaped by a fragmented regulatory environment, intense competition from licensed and illicit market participants, and ongoing liquidity constraints. CV Sciences has also been reducing costs and delaying discretionary spending to preserve capital while it seeks to stabilize revenue and fund growth initiatives.

## Products & services

• Hemp-derived CBD consumer products
• Herbal supplement products
• New product launches under existing brands
• Contract manufacturing services
• CBD-based novel therapeutics development
• Quality assurance and product testing protocols

- **CBD consumer products** (70%) — Branded hemp-derived CBD products sold to consumers through retail and other channels.
- **Herbal supplements** (15%) — Supplement products that compete in adjacent wellness and nutraceutical categories.
- **Contract manufacturing** (10%) — Third-party manufacturing revenue tied to producing products for other customers.
- **CBD therapeutics development** (5%) — Early-stage drug development work focused on CBD-based novel therapeutics.

- Hemp-derived CBD consumer products
- Herbal supplement products
- New product launches under existing brands
- Contract manufacturing services
- CBD-based novel therapeutics development
- Quality assurance and product testing protocols

## Customers

CV Sciences sells primarily to consumers seeking hemp-derived CBD and wellness products, with demand driven by brand trust, product availability, and perceived quality. The company also serves customers that buy through third-party channels and may generate revenue from contract manufacturing relationships. Its customer base is highly price- and availability-sensitive because the market has low barriers to entry and many substitute products. The company’s reports also indicate that new products are an important source of sales, suggesting repeat buyers and trial-driven wellness consumers are a meaningful segment. Because regulation varies by state, customer access and product assortment can differ materially by geography.

- **CBD wellness consumers** (primary) — Buy hemp-derived CBD products for wellness, recovery, or general health use and choose based on brand, quality, and availability.
- **Herbal supplement consumers** (secondary) — Buy adjacent supplement products that overlap with the company’s wellness positioning and broaden the basket size.
- **Channel and retail partners** (secondary) — Purchase products for resale because branded CBD and supplement items can generate consumer demand through distribution networks.
- **Contract manufacturing customers** (emerging) — Use the company for third-party production when they need manufacturing capacity and product formulation support.

- Consumers buying CBD wellness products for daily use and symptom relief
- Herbal supplement buyers seeking adjacent wellness products
- Retail and channel partners that resell branded consumer products
- Third-party customers using contract manufacturing capabilities
- Customers attracted by new product launches and brand recognition
- Buyers in states where CBD access is shaped by local regulation

## Geography

CV Sciences is headquartered in the United States and appears to generate most of its business there, with operations and customer demand shaped by U.S. state-level CBD regulation. The company’s primary offices and facilities are in San Diego, California; Grand Junction, Colorado; and Warsaw, Poland, indicating a mix of U.S. commercial and manufacturing/operational support locations. Management also references a globally expanding market, but the disclosed business remains centered on U.S. consumer demand and domestic regulatory conditions. The patchwork of state rules is important because it affects product availability, sales execution, and the risk of out-of-stock situations. The Warsaw, Poland facility suggests some international operating footprint, but no country-level revenue split was disclosed in the provided excerpts.

- United States is the core market for sales and regulatory exposure
- San Diego, California is a primary office and operating location
- Grand Junction, Colorado supports manufacturing or operational activity
- Warsaw, Poland indicates an international facility footprint
- State-by-state CBD regulation affects where products can be sold
- No country-level revenue disclosure was provided in the excerpts

## Strategy

CV Sciences is focused on rebuilding and diversifying its consumer products platform while preserving liquidity. Management is emphasizing new product innovation, brand awareness, quality assurance, and continued research and development to defend share in a crowded CBD market. The company also intends to pursue acquisitions to broaden its product offering and has engaged an investment banker to evaluate strategic alternatives, including mergers, sales, and other transactions. At the same time, it is cutting costs, reducing headcount and vendor spending, and delaying some drug development expenses to align spending with available capital. The strategy reflects a balance between growth investment and survival-oriented capital management.

- **New product innovation and launches** (short-term) — New products are a key lever for revenue growth in a market where customers can easily switch to competitors.
- **Cost reduction and liquidity preservation** (short-term) — The company has negative operating cash flow and a going-concern risk, so preserving cash is essential to continue operations.
- **Platform diversification through acquisitions** (medium-term) — Acquisitions could broaden the product mix and reduce dependence on a single CBD category.
- **CBD therapeutics development** (long-term) — The drug development program could create a higher-value pipeline if capital becomes available.

- Launch new products to offset competitive pressure and support repeat demand
- Build brand awareness in a fragmented CBD market
- Strengthen quality assurance to differentiate from lower-quality competitors
- Pursue acquisitions to diversify product offerings
- Evaluate strategic alternatives with financial advisors
- Reduce costs and delay discretionary spending to conserve cash
- Maintain optionality for debt, equity, or credit financing

## Risks

CV Sciences faces substantial business risk from a fragmented and weakly regulated CBD market, where licensed and illicit competitors can quickly undercut pricing and capture customers. The company has also disclosed temporary manufacturing constraints and out-of-stock issues, which can directly reduce near-term revenue and damage customer retention. Liquidity is a major concern because the company has negative operating cash flow, an accumulated deficit, and dependence on external financing to fund operations. More broadly, CBD and supplement businesses face regulatory uncertainty, product quality and compliance risk, and demand volatility as consumer preferences shift. Any failure to raise capital on acceptable terms could materially affect the company’s ability to continue as a going concern.

- **Regulatory uncertainty in CBD markets** [high] — The company operates in a market with a lack of a clear regulatory framework and patchwork state rules, which can restrict sales and increase compliance costs.
- **Liquidity and going-concern risk** [critical] — Negative operating cash flow, an accumulated deficit, and reliance on debt or capital markets create a risk that funding may not be available when needed.
- **Manufacturing and supply disruptions** [high] — Out-of-stock issues and manufacturing constraints can reduce sales, hurt customer retention, and delay revenue recognition timing.
- **Competitive pressure from low-barrier entrants** [high] — Licensed and illicit operators can offer substitute products, pressuring pricing, margins, and market share.
- **Execution risk on acquisitions and strategic changes** [medium] — The company is pursuing acquisitions and strategic alternatives while also cutting costs, which can distract management and create integration risk.

- Intense competition from licensed and illicit CBD sellers
- Regulatory uncertainty across states and lack of a clear framework
- Temporary manufacturing constraints causing out-of-stock situations
- Dependence on external financing to fund operations
- Going-concern risk due to negative cash flow and accumulated deficit
- Customer switching risk in a low-barrier consumer market
- Execution risk around acquisitions and product diversification

## Accounting

CV Sciences’ financial reporting is heavily influenced by going-concern judgments, liquidity assumptions, and estimates around debt and contingent liabilities. The company disclosed a reversal of a $0.5 million payroll tax contingent liability after the statute of limitations expired, showing that changes in legal or tax assumptions can materially affect reported earnings. It also recorded interest expense and debt discount amortization on secured promissory notes, which affects other expense and reported net loss even when cash proceeds are modest. Revenue can be volatile because product sales are sensitive to out-of-stock issues, channel mix, and new product launches, making quarter-to-quarter comparisons less stable. Investors should also watch inventory and manufacturing-related estimates, since supply constraints can affect both sales timing and cost of goods sold.

- **Going-concern disclosure** — Can affect asset valuation, liability classification, and investor assessment of solvency
- **Debt discount and issuance cost amortization** — Impacts net loss and financing cost analysis
- **Contingent liability estimate reversal** — Can create non-recurring gains or losses
- **Revenue and inventory timing** — Affects revenue comparability and gross profit

- Going-concern assessment depends on future financing and cash generation
- Debt discount and issuance cost amortization affects other expense
- Contingent liability reversals can create one-time gains in earnings
- Revenue timing can be affected by product availability and out-of-stock issues
- Inventory and manufacturing estimates influence cost of goods sold
- Quarterly comparability is affected by new product launches and channel mix

---

*Last updated: 2026-08-11T04:46:27.353948+00:00*